The brilliance of Cross should take this to new highs soon enough!
Hats of to KBIO management, when you bring in a winner -- it usually results in enormous upside. I think you had a classic bear raid on Friday, now expect some huge upside as KBIO breaks out. Just having Cross at the helm my deserve a double in share value from here over the next few months. The brilliance of Cross at overseeing successful monoclonal antibody therapeutic trials-- could bring KBIO as high as $50 a share in two years.